Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02353741
Other study ID # XQonc-001
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 2015
Est. completion date December 1, 2018

Study information

Verified date December 2018
Source Xinqiao Hospital of Chongqing
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-arm phase II study aims to study the efficacy of a possible first line treatment that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this new combinational therapy can benefit short-term and long-term survival of the patients with advanced NSCLC.


Description:

Based on NCCN guideline of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) such as erlotinib, gefitinib and icotinib as the first line treatment for advanced Non-Small Cell Lung Cancer (NSCLC), the efficacy of EGFR-TKIs in combination with thoracic radiotherapy as the first line treatment for stage IV NSCLC with active EGFR mutation remains unknown. In this single-arm phase II trial, we chose the subjects with stage IV harboring active EGFR mutation,who were treated by EGFR-TKIs combined with radiation therapy. The primary endpoint is 1-year rate of progression-free survival and the second endpoints are overall survival (OS), objective response rate and toxic and side effect. By evaluating them, we expect to find out the evidence that the combination therapy can benefit the short-term and long-term survival of the patients. Meanwhile, via the stratification analysis of tumor biomarker and immune index, we obtain the evidences for the benefits of comprehensive and individual treatment for advanced NSCLC.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date December 1, 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. ECOG performance status=2;

2. Cytologically or pathologically confirmed stage IV NSCLC ( controlled pleural effusion will be eligible) with active EGFR mutation;

3. Estimated survival time more than 3 months;

4. Age older than 18 years and under 75 years;

5. Adequate bone marrow, hepatic, and renal function;AST and ALT=2.5 times the highest reference value when not associated with hepatic metastases, or =5 times when hepatic metastases occur;

6. Without history of therapy for primary and metastatic disease;

7. With pleural effusion but can be controlled;

8. Asymptomatic bone metastases without treatment;

9. Based on fusion images of 4DCT MIP sketch tumors and lymph nodes, and limit the mean lung dose: V20=25%,V30=18%,MLD=14Gy,V5=60%;

10. M1a or M1b for metastases, and the number of the distant lesions =10;

11. Voluntary to participate in this clinical trial and sign the consent form.

Exclusion Criteria:

1. Patients with serious functional damage of important organs;

2. Patients diagnosed adequately with other malignant tumors;

3. Pregnant or lactating women;

4. Patients in an active period of acute or chronic infectious diseases;

5. Patients who are allergic to any drugs or people with allergies;

6. With brain metastases;

7. With bone metastases needing radiotherapy;

8. Patients who participate in other clinical trials concurrently;

9. Uncontrolled pleural effusion which may intervene the radiotherapy to primary tumor in lung;

10. The number of the distant lesions>10;

11. Patients who are considered not eligible for the trial after evaluation by investigator.

Study Design


Intervention

Drug:
EGFR-TKIs
Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
Radiation:
thoracic radiotherapy
From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54~60Gy/27~30f/5.5~6w.

Locations

Country Name City State
China Xinqiao Hospital of Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1-year rate of progression-free survival 1-year rate of progression-free survival one year after treatment, followed
Secondary Overall survival (OS) Overall survival (OS) From the time of study enrollment until the date of death
Secondary Objective response rate Assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) up to three years
Secondary Disease control rate Assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) up to three years
Secondary patients quality of life Assessed by EORTC-QLQ C30 up to three years
Secondary Failure mode The number of patients who failed the treatment of EGFR-TKIs with thoracic radiotherapy. up to three years
Secondary Toxicities associated with combined erlotinib and concurrent thoracic radiotherapy. Assessed by Common Terminology Criteria for Adverse Events(CTCAE) Assessed by Common Terminology Criteria for Adverse Events(CTCAE) up to three years
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1